NT5E and posterior cortical atrophy: Clinical trials combining a CD73 Inhibitor, LY3475070 (NCT04148937) or CPI-006 (NCT03454451) alone or in combination with pembrolizumab in patients with advanced cancers, including PCa are currently ongoing.